Kodak's Patent Allure Fades
Value Tarnished After Invalidation Ruling; Portfolio Lacks Stalking-Horse Bid — Eastman Kodak Co.'s effort to draw interest in the sale of its digital patent portfolio is flagging, people familiar with the matter said, complicating the 132-year-old photography …
Context & Ripple Effects
The sale of Kodak's digital imaging patents was meant to be the financial centerpiece of its restructuring. The company entered 2012 already weakened: an adverse ITC ruling had derailed its push for royalties from Apple and Research In Motion the year before, and by January it was preparing a Chapter 11 filing that closed on January 19. CEO Antonio Perez had publicly pegged a win in the Apple/RIM dispute at more than $1 billion in royalty revenue, making the patent estate the asset the whole plan leaned on.
Now the auction itself is stalling: an invalidation ruling has tarnished the portfolio's value and no stalking-horse bid has emerged to set a price floor. With UPI among outlets picking up the story, the failure to attract even an anchor bidder turns what was framed as a monetization engine into a distressed asset with an uncertain market.
First-order effects
- Kodak's Chapter 11 exit math loses its anchor: without a stalking-horse bid, creditors have no credible valuation for the patent portfolio that was supposed to fund repayment.
- The invalidation ruling directly cuts the enforceable scope of the digital imaging patents, shrinking what any buyer would actually be purchasing.
Second-order effects
- Litigation targets like Apple and RIM lose settlement pressure — with the ITC path already derailed and the portfolio's validity questioned, Kodak's leverage to extract royalties weakens on both fronts.
- Deep-pocketed potential bidders can afford to wait for prices to fall further, since every week without a stalking-horse bid lowers the estate's bargaining position.
Third-order effects
- If invalidation risk can gut a flagship portfolio mid-auction, patent sales become harder to underwrite as bankruptcy funding across tech — buyers will discount for litigation exposure, not just pay for paper claims.
- Kodak's trajectory illustrates the broader repricing of legacy R&D estates: patents tied to expired product franchises trade on courtroom durability rather than invention count.
The trend: Tech bankruptcies are learning that patent portfolios function as collateral only when their enforceability holds up under legal attack, shifting distress monetization from patent auctions toward operating assets.